Atlas Capital Advisors’s TScan Therapeutics TCRX Stock Holding History

Atlas Capital Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$26	Hold	18	–	–	﹤0.01%	919
2025 Q1	$24	Hold	18	–	–	﹤0.01%	979
2024 Q4	$54	Hold	18	–	–	﹤0.01%	921
2024 Q3	$89	Hold	18	–	–	﹤0.01%	897
2024 Q2	$105	Hold	18	–	–	﹤0.01%	884
2024 Q1	$142	Sell	18 -878	-98%	-$5.52K	﹤0.01%	877
2023 Q4	$5.22K	Hold	896	–	–	﹤0.01%	790
2023 Q3	$2.29K	Hold	896	–	–	﹤0.01%	801
2023 Q2	$2.24K	Hold	896	–	–	﹤0.01%	821
2023 Q1	$1.88K	Hold	896	–	–	﹤0.01%	837
2022 Q4	$1.39K	Hold	896	–	–	﹤0.01%	844
2022 Q3	$2.73K	Hold	896	–	–	﹤0.01%	819
2022 Q2	$2.82K	Buy	+896	New	+$2.45K	﹤0.01%	892

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Atlas Capital Advisors's TCRX Position: Q2 2025 in Review

Atlas Capital Advisors held its TScan Therapeutics (TCRX) position steady in Q2 2025 at 18 shares worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #919.

Atlas Capital Advisors first reported a position in TCRX in Q2 2022 and has held it in 13 quarters since. The position peaked at $5.22K in Q4 2023. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

Atlas Capital Advisors held 18 shares of TScan Therapeutics worth $26 as of Q2 2025.
Atlas Capital Advisors left its TScan Therapeutics share count unchanged in Q2 2025.
TScan Therapeutics made up ﹤0.01% of Atlas Capital Advisors's portfolio in Q2 2025, its #919 holding.
Atlas Capital Advisors first reported a position in TScan Therapeutics in Q2 2022 and has held it in 13 quarters since.
Atlas Capital Advisors's TScan Therapeutics position peaked at $5.22K in Q4 2023.
81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on Atlas Capital Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.